Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year treatment period, according to long-term extension data presented at the ...

Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.

The Business Research Company The Business Research Company's Prurigo Nodularis Treatment Global Market Report 2025 – Market Size, Trends, ...

ZUG, Switzerland, June 18, 2025--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe ...

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis ...

The firm’s CHF 133 price target implies nearly 9% upside from current levels. Barclays also initiated Zealand Pharma with an Overweight rating and DKK 560 price target, pointing to a compelling ...

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US ...

The drug already holds approvals to treat prurigo nodularis, as well as atopic dermatitis, another chronic skin condition. Commenting on the latest results for the drug, Baldo Scassellati Sforzolini, ...